Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors - PubMed (original) (raw)
Review
Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors
Francois Romagne. Drug Discov Today. 2007 Jan.
Abstract
Innate immunity receptors are germline-encoded receptors that can sense molecular signatures of pathogens and cancer cells. Recent advances in immunology demonstrate the key role of these receptors in inflammation and initiation of subsequent immune responses, including adaptive immunity. Pharmaceutical interest in this field has grown with the retrospective demonstration that some marketed drugs targeting cancer or infectious diseases act via those receptors. In this review, I present an update on the scientific rationale for targeting one class of innate immunity receptor, the Toll-like receptors, and an update on the development status of corresponding drug candidates in infectious diseases, cancer, allergy and vaccines.
Similar articles
- Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.
Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Kanzler H, et al. Nat Med. 2007 May;13(5):552-9. doi: 10.1038/nm1589. Nat Med. 2007. PMID: 17479101 Review. - The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
Makkouk A, Abdelnoor AM. Makkouk A, et al. Immunopharmacol Immunotoxicol. 2009;31(3):331-8. doi: 10.1080/08923970902802926. Immunopharmacol Immunotoxicol. 2009. PMID: 19555209 Review. - Drugs targeting Toll-like receptors.
Krishnan J, Lee G, Choi S. Krishnan J, et al. Arch Pharm Res. 2009 Nov;32(11):1485-502. doi: 10.1007/s12272-009-2100-6. Arch Pharm Res. 2009. PMID: 20091261 Review. - The future of toll-like receptor therapeutics.
Parkinson T. Parkinson T. Curr Opin Mol Ther. 2008 Feb;10(1):21-31. Curr Opin Mol Ther. 2008. PMID: 18228178 Review. - Innate immunity: toll-like receptors and some more. A brief history, basic organization and relevance for the human newborn.
Fleer A, Krediet TG. Fleer A, et al. Neonatology. 2007;92(3):145-57. doi: 10.1159/000102054. Epub 2007 Apr 27. Neonatology. 2007. PMID: 17476116 Review.
Cited by
- Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.
Nguyen DN, Mahon KP, Chikh G, Kim P, Chung H, Vicari AP, Love KT, Goldberg M, Chen S, Krieg AM, Chen J, Langer R, Anderson DG. Nguyen DN, et al. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):E797-803. doi: 10.1073/pnas.1121423109. Epub 2012 Mar 15. Proc Natl Acad Sci U S A. 2012. PMID: 22421433 Free PMC article. - Timing is critical for an effective anti-metastatic immunotherapy: the decisive role of IFNγ/STAT1-mediated activation of autophagy.
Yan J, Wang ZY, Yang HZ, Liu HZ, Mi S, Lv XX, Fu XM, Yan HM, Zhang XW, Zhan QM, Hu ZW. Yan J, et al. PLoS One. 2011;6(9):e24705. doi: 10.1371/journal.pone.0024705. Epub 2011 Sep 13. PLoS One. 2011. PMID: 21931823 Free PMC article. - Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly.
Kollmann TR, Levy O, Montgomery RR, Goriely S. Kollmann TR, et al. Immunity. 2012 Nov 16;37(5):771-83. doi: 10.1016/j.immuni.2012.10.014. Immunity. 2012. PMID: 23159225 Free PMC article. Review. - Toll-like receptors in skin infections and inflammatory diseases.
Lai Y, Gallo RL. Lai Y, et al. Infect Disord Drug Targets. 2008 Sep;8(3):144-55. doi: 10.2174/1871526510808030144. Infect Disord Drug Targets. 2008. PMID: 18782031 Free PMC article. Review. - Potential of immunomodulatory host defense peptides as novel anti-infectives.
Easton DM, Nijnik A, Mayer ML, Hancock RE. Easton DM, et al. Trends Biotechnol. 2009 Oct;27(10):582-90. doi: 10.1016/j.tibtech.2009.07.004. Epub 2009 Aug 14. Trends Biotechnol. 2009. PMID: 19683819 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources